{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:29:03Z","timestamp":1790731743813,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["NCT03069352"],"award-info":[{"award-number":["NCT03069352"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["NCT02993523"],"award-info":[{"award-number":["NCT02993523"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN)\u2009+\u2009(AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO)\u2009+\u2009AZA or LDAC. Patient-reported outcomes included: EORTC QLQ-C30 global health status (GHS\/QoL) and physical functioning (PF), PROMIS Cancer Fatigue Short Form 7a (Fatigue), and EQ-5D-5L health status visual analog scale (HS-VAS). Time to deterioration (TTD), defined as worsening from baseline in meaningful change thresholds (MCT) of \u226510, 5, or 7 points for GHS\/QoL or PF, fatigue, and HS-VAS, respectively, was assessed; differences between groups were analyzed using Kaplan-Meier and unadjusted log-rank analyses. VEN\u2009+\u2009AZA vs PBO\u2009+\u2009AZA patients had longer TTD in GHS\/QoL (<jats:italic>P<\/jats:italic>\u2009=\u20090.066) and fatigue (<jats:italic>P<\/jats:italic>\u2009=\u20090.189), and significantly longer TTD in PF (<jats:italic>P<\/jats:italic>\u2009=\u20090.028) and HS-VAS (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). VEN\u2009+\u2009LDAC vs PBO\u2009+\u2009LDAC patients had significantly longer TTD in GHS\/QoL (<jats:italic>P<\/jats:italic>\u2009=\u20090.011), <jats:italic>P<\/jats:italic>F (<jats:italic>P<\/jats:italic>\u2009=\u20090.020), and fatigue (<jats:italic>P<\/jats:italic>\u2009=\u20090.004), and a trend in HS-VAS (<jats:italic>P<\/jats:italic>\u2009=\u20090.057). Approximately 43%, 35%, 32%, and 18% of patients treated with VEN\u2009+\u2009AZA, AZA\u2009+\u2009PBO, VEN\u2009+\u2009LDAC, or LDAC\u2009+\u2009PBO, respectively, saw improvements &gt;MCT in GHS\/QoL. Overall, VEN may positively impact HRQoL in patients with AML ineligible for intensive chemotherapy, leading to longer preservation of functioning and overall health status.<\/jats:p>","DOI":"10.1038\/s41408-022-00668-8","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T12:03:38Z","timestamp":1650456218000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Venetoclax combinations delay the time to deterioration of HRQoL in unfit patients with acute myeloid leukemia"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-8266","authenticated-orcid":false,"given":"Keith W.","family":"Pratz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panayiotis","family":"Panayiotidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3332-4525","authenticated-orcid":false,"given":"Christian","family":"Recher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4921-5809","authenticated-orcid":false,"given":"Brian A.","family":"Jonas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3275-5593","authenticated-orcid":false,"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Ivanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney D.","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Novak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlatko","family":"Pejsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"Stevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Peng","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Turgut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fracchiolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8588-8955","authenticated-orcid":false,"given":"Kazuhito","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishai","family":"Ofran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cat N.","family":"Bui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Benjamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kamalakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalaja","family":"Potluri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0733-8456","authenticated-orcid":false,"given":"Wellington","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Devine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"668_CR1","unstructured":"Howlader N, Noone A, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, based on November 2019 SEER data submission, posted to the SEER website, April 2020 [Available from: https:\/\/seer.cancer.gov\/archive\/csr\/1975_2017\/."},{"key":"668_CR2","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129:424\u201347.","journal-title":"Blood"},{"key":"668_CR3","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","volume":"129","author":"M Levis","year":"2017","unstructured":"Levis M. Midostaurin approved for FLT3-mutated AML. Blood 2017;129:3403\u201306.","journal-title":"Blood"},{"key":"668_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-019-0175-x","volume":"7","author":"B Yu","year":"2019","unstructured":"Yu B, Liu D. Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia. Biomark Res. 2019;7:24.","journal-title":"Biomark Res"},{"key":"668_CR5","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1182\/blood-2014-08-551499","volume":"125","author":"G Ossenkoppele","year":"2015","unstructured":"Ossenkoppele G, L\u00f6wenberg B. How I treat the older patient with acute myeloid leukemia. Blood 2015;125:767\u201374.","journal-title":"Blood"},{"key":"668_CR6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1159\/000486228","volume":"139","author":"X Song","year":"2018","unstructured":"Song X, Peng Y, Wang X, Chen Y, Jin L, Yang T, et al. Incidence, survival, and risk factors for adults with acute myeloid leukemia not otherwise specified and acute myeloid leukemia with recurrent genetic abnormalities: analysis of the surveillance, epidemiology, and end results (SEER) database, 2001\u20132013. Acta Haematologica. 2018;139:115\u201327.","journal-title":"Acta Haematologica"},{"key":"668_CR7","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1002\/cncr.28129","volume":"119","author":"MS Thein","year":"2013","unstructured":"Thein MS, Ershler WB, Jemal A, Yates JW, Baer MR. Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer 2013;119:2720\u20137.","journal-title":"Cancer"},{"key":"668_CR8","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1200\/JCO.2015.64.0060","volume":"34","author":"S Amadori","year":"2016","unstructured":"Amadori S, Suciu S, Selleslag D, Aversa F, Gaidano G, Musso M, et al. Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 Trial. J Clin Oncol. 2016;34:972\u20139.","journal-title":"J Clin Oncol"},{"key":"668_CR9","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/cncr.22496","volume":"109","author":"AK Burnett","year":"2007","unstructured":"Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007;109:1114\u201324.","journal-title":"Cancer"},{"key":"668_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015;126:291\u201399.","journal-title":"Blood"},{"key":"668_CR11","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30:2670\u20137.","journal-title":"J Clin Oncol"},{"key":"668_CR12","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1016\/j.clml.2019.11.017","volume":"20","author":"EM Stein","year":"2020","unstructured":"Stein EM, DiNardo CD, Pollyea DA, Schuh AC. Response kinetics and clinical benefits of nonintensive AML therapies in the absence of morphologic response. Clin Lymphoma Myeloma Leuk. 2020;20:e66\u2013e75.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"668_CR13","unstructured":"AbbVie. VENCLEXTA [Prescribing information] Available from: https:\/\/www.rxabbvie.com\/pdf\/venclexta.pdf."},{"key":"668_CR14","unstructured":"US Food Drug Administration. FDA approves venetoclax in combination for AML in adults [Available from: https:\/\/www.fda.gov\/drugs\/fda-approves-venetoclax-combination-aml-adults."},{"key":"668_CR15","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl J Med. 2020;383:617\u201329.","journal-title":"N. Engl J Med"},{"key":"668_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 2019;133:7\u201317.","journal-title":"Blood"},{"key":"668_CR17","doi-asserted-by":"publisher","first-page":"204062071988282","DOI":"10.1177\/2040620719882822","volume":"10","author":"G Richard-Carpentier","year":"2019","unstructured":"Richard-Carpentier G, DiNardo CD. Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy. Ther Adv Hematol. 2019;10:2040620719882822.","journal-title":"Ther Adv Hematol"},{"key":"668_CR18","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V, DiNardo CD, Novak J, Laribi K, et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 2020;135:2137\u201345.","journal-title":"Blood"},{"key":"668_CR19","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1200\/JCO.18.01600","volume":"37","author":"AH Wei","year":"2019","unstructured":"Wei AH, Strickland SA Jr., Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib\/II study. J Clin Oncol. 2019;37:1277\u201384.","journal-title":"J Clin Oncol"},{"key":"668_CR20","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/bloodadvances.2019000243","volume":"3","author":"AC Winters","year":"2019","unstructured":"Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3:2911\u201319.","journal-title":"Blood Adv"},{"key":"668_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/cncr.30982","volume":"124","author":"SA Buckley","year":"2018","unstructured":"Buckley SA, Jimenez-Sahagun D, Othus M, Walter RB, Lee SJ. Quality of life from the perspective of the patient with acute myeloid leukemia. Cancer 2018;124:145\u201352.","journal-title":"Cancer"},{"key":"668_CR22","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.2217\/fon-2018-0842","volume":"15","author":"CM Mamolo","year":"2019","unstructured":"Mamolo CM, Cappelleri JC, Hoang CJ, Kim R, Hadfield A, Middleton C, et al. A real-world, cross-sectional, community survey of symptoms and health-related quality of life of adults with acute myeloid leukemia. Future Oncol. 2019;15:1895\u2013909.","journal-title":"Future Oncol"},{"key":"668_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s40487-016-0029-8","volume":"4","author":"EL Tomaszewski","year":"2016","unstructured":"Tomaszewski EL, Fickley CE, Maddux L, Krupnick R, Bahceci E, Paty J, et al. The patient perspective on living with acute myeloid leukemia. Oncol Ther. 2016;4:225\u201338.","journal-title":"Oncol Ther"},{"key":"668_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40487-016-0039-6","volume":"5","author":"EE Korol","year":"2017","unstructured":"Korol EE, Wang S, Johnston K, Ravandi-Kashani F, Levis M, van Nooten F. Health-related quality of life of patients with acute myeloid leukemia: a systematic literature review. Oncol Ther. 2017;5:1\u201316.","journal-title":"Oncol Ther"},{"key":"668_CR25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3324\/haematol.2012.067892","volume":"98","author":"B Deschler","year":"2013","unstructured":"Deschler B, Ihorst G, Platzbecker U, Germing U, M\u00e4rz E, de Figuerido M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica 2013;98:208\u201316.","journal-title":"Haematologica"},{"key":"668_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/CEOR.S187409","volume":"11","author":"A Forsythe","year":"2019","unstructured":"Forsythe A, Kwon CS, Bell T, Smith TA, Arondekar B. Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review. Clinicoecon Outcomes Res. 2019;11:87\u201398.","journal-title":"Clinicoecon Outcomes Res"},{"key":"668_CR27","doi-asserted-by":"publisher","first-page":"696","DOI":"10.3324\/haematol.2010.036715","volume":"96","author":"EN Oliva","year":"2011","unstructured":"Oliva EN, Nobile F, Alimena G, Ronco F, Specchia G, Impera S, et al. Quality of life in elderly patients with acute myeloid leukemia: patients may be more accurate than physicians. Haematologica 2011;96:696\u2013702.","journal-title":"Haematologica"},{"key":"668_CR28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/ejh.13389","volume":"104","author":"R Stauder","year":"2020","unstructured":"Stauder R, Lambert J, Desruol-Allardin S, Savre I, Gaugler L, Stojkov I, et al. Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis. Eur J Haematol. 2020;104:476\u201387.","journal-title":"Eur J Haematol"},{"key":"668_CR29","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/j.ejca.2008.03.017","volume":"44","author":"F Efficace","year":"2008","unstructured":"Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B. Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials\u2013a systematic review to evaluate the added value in supporting clinical decision making. Eur J Cancer. 2008;44:1497\u2013506.","journal-title":"Eur J Cancer"},{"key":"668_CR30","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.critrevonc.2015.07.012","volume":"96","author":"L Cannella","year":"2015","unstructured":"Cannella L, Caocci G, Jacobs M, Vignetti M, Mandelli F, Efficace F. Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: what have we learned? Crit Rev Oncol Hematol. 2015;96:542\u201354.","journal-title":"Crit Rev Oncol Hematol"},{"key":"668_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40487-019-0094-x","volume":"7","author":"LE Horvath Walsh","year":"2019","unstructured":"Horvath Walsh LE, Rider A, Piercy J, Pike J, Wilson S, Pandya BJ, et al. Real-world impact of physician and patient discordance on health-related quality of life in US patients with acute myeloid leukemia. Oncol Ther. 2019;7:67\u201381.","journal-title":"Oncol Ther"},{"key":"668_CR32","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","volume":"85","author":"NK Aaronson","year":"1993","unstructured":"Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365\u201376.","journal-title":"J Natl Cancer Inst"},{"key":"668_CR33","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jclinepi.2015.08.037","volume":"73","author":"D Cella","year":"2016","unstructured":"Cella D, Lai JS, Jensen SE, Christodoulou C, Junghaenel DU, Reeve BB, et al. PROMIS fatigue item bank had clinical validity across diverse chronic conditions. J Clin Epidemiol. 2016;73:128\u201334.","journal-title":"J Clin Epidemiol"},{"key":"668_CR34","doi-asserted-by":"publisher","first-page":"5106","DOI":"10.1200\/JCO.2007.12.2341","volume":"25","author":"SF Garcia","year":"2007","unstructured":"Garcia SF, Cella D, Clauser SB, Flynn KE, Lad T, Lai JS, et al. Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J Clin Oncol. 2007;25:5106\u201312.","journal-title":"J Clin Oncol"},{"key":"668_CR35","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M Herdman","year":"2011","unstructured":"Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727\u201336.","journal-title":"Qual Life Res"},{"key":"668_CR36","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.jval.2014.04.002","volume":"17","author":"M Oppe","year":"2014","unstructured":"Oppe M, Devlin NJ, van Hout B, Krabbe PF, de Charro F. A program of methodological research to arrive at the new international EQ-5D-5L valuation protocol. Value Health. 2014;17:445\u201353.","journal-title":"Value Health"},{"key":"668_CR37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","volume":"16","author":"D Osoba","year":"1998","unstructured":"Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139\u201344.","journal-title":"J Clin Oncol"},{"key":"668_CR38","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1477-7525-5-70","volume":"5","author":"AS Pickard","year":"2007","unstructured":"Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70.","journal-title":"Health Qual Life Outcomes"},{"key":"668_CR39","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1038\/sj.leu.2403289","volume":"18","author":"MA Sekeres","year":"2004","unstructured":"Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004;18:809\u201316.","journal-title":"Leukemia"},{"key":"668_CR40","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3324\/haematol.2012.066613","volume":"98","author":"MA Sekeres","year":"2013","unstructured":"Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, et al. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica 2013;98:119\u201328.","journal-title":"Haematologica"},{"key":"668_CR41","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1200\/JCO.2002.04.044","volume":"20","author":"AB Kornblith","year":"2002","unstructured":"Kornblith AB, Herndon JE 2nd, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441\u201352.","journal-title":"J Clin Oncol"},{"key":"668_CR42","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"M L\u00fcbbert","year":"2011","unstructured":"L\u00fcbbert M, Suciu S, Baila L, R\u00fcter BH, Platzbecker U, Giagounidis A, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29:1987\u201396.","journal-title":"J Clin Oncol"},{"key":"668_CR43","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s13670-017-0227-8","volume":"6","author":"S Storey","year":"2017","unstructured":"Storey S, Gray TF, Bryant AL. Comorbidity, physical function, and quality of life in older adults with acute myeloid leukemia. Curr Geriatr Rep. 2017;6:247\u201354.","journal-title":"Curr Geriatr Rep"},{"key":"668_CR44","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1002\/cncr.21792","volume":"106","author":"H Kantarjian","year":"2006","unstructured":"Kantarjian H, Issa J-PJ, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes. Cancer 2006;106:1794\u2013803.","journal-title":"Cancer"},{"key":"668_CR45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.blre.2017.08.010","volume":"32","author":"SA Buckley","year":"2018","unstructured":"Buckley SA, Kirtane K, Walter RB, Lee SJ, Lyman GH. Patient-reported outcomes in acute myeloid leukemia: where are we now? Blood Rev. 2018;32:81\u201387.","journal-title":"Blood Rev"},{"key":"668_CR46","first-page":"1437","volume":"26","author":"N Kayastha","year":"2018","unstructured":"Kayastha N, Wolf SP, Locke SC, Samsa GP, El-Jawahri A, LeBlanc TW. The impact of remission status on patients\u2019 experiences with acute myeloid leukemia (AML): an exploratory analysis of longitudinal patient-reported outcomes data. Support Care Cancer. 2018;26:1437\u201345.","journal-title":"Support Care Cancer"},{"key":"668_CR47","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1038\/s41375-019-0449-1","volume":"33","author":"A El-Jawahri","year":"2019","unstructured":"El-Jawahri A, Abel GA, Traeger L, Waldman L, Markovitz N, VanDusen H, et al. Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapy. Leukemia 2019;33:2393\u2013402.","journal-title":"Leukemia"},{"key":"668_CR48","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.jval.2011.11.032","volume":"15","author":"A Gnanasakthy","year":"2012","unstructured":"Gnanasakthy A, Mordin M, Clark M, DeMuro C, Fehnel S, Copley-Merriman C. A review of patient-reported outcome labels in the United States: 2006 to 2010. Value Health 2012;15:437\u201342.","journal-title":"Value Health"},{"key":"668_CR49","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.jval.2013.08.2293","volume":"16","author":"C DeMuro","year":"2013","unstructured":"DeMuro C, Clark M, Doward L, Evans E, Mordin M, Gnanasakthy A. Assessment of PRO label claims granted by the FDA as compared to the EMA (2006\u20132010). Value Health. 2013;16:1150\u201355.","journal-title":"Value Health"},{"key":"668_CR50","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1359-6349(12)70023-X","volume":"10","author":"G Velikova","year":"2012","unstructured":"Velikova G, Coens C, Efficace F, Greimel E, Groenvold M, Johnson C, et al. Health-related quality of life in EORTC clinical trials\u201430 years of progress from methodological developments to making a real impact on oncology practice. Eur J Cancer. 2012;10:141\u201349.","journal-title":"Eur J Cancer"},{"key":"668_CR51","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1080\/10428194.2019.1709838","volume":"61","author":"SA Buckley","year":"2020","unstructured":"Buckley SA, Halpern AB, Othus M, Jimenez-Sahagun D, Walter RB, Lee SJ. Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia. Leuk Lymphoma. 2020;61:1158\u201367.","journal-title":"Leuk Lymphoma"},{"key":"668_CR52","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3389\/fphar.2020.01109","volume":"11","author":"M Salas","year":"2020","unstructured":"Salas M, Henderson M, Wientzek-Fleischmann A, Islam Z, Tu N, Bilitou A, et al. Validated instruments of quality of life (QOL) in patients with acute myeloid leukemia (AML) and other cancers. Front Pharm. 2020;11:1109.","journal-title":"Front Pharm"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00668-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00668-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00668-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T20:07:47Z","timestamp":1669234067000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00668-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00668-8","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"assertion":[{"value":"21 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"KWP: grant support and advisory board fees from AbbVie, Astellas, Agios, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Jazz Pharmaceuticals, Servier, and Millennium; grant support from Astellas, Boston BioMedical, Celgene, Jazz Pharmaceuticals. PP: grant and research support from AbbVie, Roche, Novartis, and Genesis; honoraria from AbbVie, Janssen, Roche, Novartis, Gilead, and GCR: Research grants from Abbvie, Amgen, Novartis, Celgene, Jazz Pharmaceuticals, Agios, Chugai, MaatPharma, Astellas, Iqvia, Roche and DS; an advisory role for Abbvie, Janssen, Jazz Pharmaceuticals, Novartis, Celgene, Otsuka, Astellas, Daiichi-Sankyo, Macrogenics, Roche, Takeda, and Pfizer. BAJ: consultant\/advisory role for AbbVie, BMS, Genentech, Gilead, GlycoMimetics, Jazz, Pfizer, Servier, Takeda, Tolero, and Treadwell; protocol steering committee for GlycoMimetics; data monitoring committee for Gilead; travel reimbursement from AbbVie; research funding to his institution from 47, AbbVie, Accelerated Medical Diagnostics, Amgen, AROG, BMS, Celgene, Daiichi Sankyo, F. Hoffmann-La Roche, Forma, Genentech\/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Incyte, Jazz, Loxo, LP Therapeutics, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell. PM: advisor\/speaker\/research support from AbbVie, Janssen, Novartis, Pfizer, and Teva; advisor\/speaker\/consultant\/research support for Astellas, Celgene, and Daiichi-Sankyo; consultant for Agios, Tolero Pharmaceuticals, Glycomimetics, and Forma Therapeutics; advisor\/speaker for Incyte and Sanofi; advisor\/research support for Karyopharm. ACS: received research funding from AbbVie, Agios, Amgen, BMS\/Celgene, Glycomimetics, Pfizer, and Novartis; advisory board member for AbbVie, Agios, Amgen, Astellas, BMS\/Celgene, Taiho, and Teva. CD: received research funding from AbbVie\/Genentech, Agios, Celgene, Daiichi Sankyo, Millennium, and Novartis and served as consultant for Agios; advisory board member for AbbVie, Agios, Bayer, Celgene, Karyopharm, and Medimmune. JN: consultant\/advisor for Novartis, Roche, Pfizer, Amgen, Takeda, and Astellas; received travel expenses from Amgen and Janssen. VP: received advisory board fees, lecture fees, and consulting fees from AbbVie, Janssen, and Amgen; advisory board fees and lecture fees from Takeda, Roche, Pliva, and Sandoz; lecture fees from Alvogen and Oktal Pharma. S-PY: advisory board member for AbbVie, Amgen, Janssen, Astellas, Astex, and Takeda. NF: honoraria from Amgen, Pfizer, Gilead, and AbbVie; speakers bureau for Amgen, Pfizer, and Gilead; advisory board for Amgen, Pfizer, Gilead, and AbbVie; travel support from Amgen, Pfizer, Gilead, and AbbVie. KY: consultancy (includes expert testimony) for AbbVie, AstraZeneca, Celgene, Chugai, Daiichi Sankyo, Eisai, HUYA, Meiji Seika Pharma, MSD, Mundipharma, Ono, Otsuka, Stemline Therapeutics and Takeda; research funding from AbbVie, Astra-Zeneca, Bayer, Celgene, Chugai, Eisai, Gilead Sciences, IQIVA\/Incyte, MSD, Mundipharma, Nippon Shinyaku, Novartis, Ono, Otsuka, Solasia Pharma, SymBio, Takeda, Yakult and Zenyaku; honoraria from AbbVie, Bristol-Myers Squibb, Celgene, Chugai, Eisai, IQIVA\/HUYA, Janssen, Kyowa Kirin, Meiji Seika Pharma, Mochida, MSD, Mundipharma, Nippon Shinyaku, Novartis, Ono, Otsuka, Pfizer, Sanofi, Sumitomo Dainippon, and Takeda. YO: has served on advisory boards for AbbVie. AHW: served in an advisory role for Astellas, AbbVie\/Genentech, Amgen, Celgene\/BMS, Novartis, Astra Zeneca, Servier, Janssen, MacroGenics, Pfizer, Gilead, and Syndax; received research funding from Astellas, Astex, AbbVie, Genentech, Amgen, Astra Zeneca, Celgene\/BMS, Novartis, Servier, and Syndax; honoraria from Astellas, AbbVie, Genentech, Amgen, Astra Zeneca, Celgene\/BMS, Novartis, Servier, Janssen, MacroGenics, Pfizer, Gilead, and Syndax; served as a consultant for: Astellas, Servier, Janssen, Gilead, and Syndax; is an employee of Walter and Eliza Hall Institute (WEHI) and is eligible for financial benefits associated with payments which WEHI receives in relation to venetoclax. WF: advisory and consulting role for Amgen; advisory role for ARIAD\/Incyte, Novartis, Pfizer; Celgene, Morphosys, AbbVie, Jazz Pharmaceuticals, and Servier; royalties from Amgen; support for meeting attendance from Amgen, Gilead, Servier, Jazz Pharmaceuticals, and Daiichi Sankyo; research funding from Amgen and Pfizer. IK, XW, VI, DS, and MT: nothing to disclose. CNB, RK, JP, and WM: employees of AbbVie and may hold stock or stock options. KB is a former employee of AbbVie and may hold stock or stock options. JD: employee of Genentech and may hold stock in the company. Venetoclax is being developed in a collaboration between AbbVie and Genentech. AbbVie and Genentech funded NCT02993523 and AbbVie funded NCT03069352 and participated in the given study design, research, analysis, data collection, interpretation of data, reviewing, and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this article. No honoraria or payments were made for authorship.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}